3/7/21

UNIVERSITY OF MARYLAND MEDICAL SYSTEM SCREENING FORM COVID-19 VACCINE SCREENING FORM

To be used before administering Pfizer-BioNTech, Moderna OR Janssen (Johnson & Johnson) vaccines

I have read or have had explained to me informathe COVID-19 vaccine.	ation made available i	in the FDA's emergency	use authorizati	on regarding	
Print Name:	Date				
Signature:	<mark>ΓΕ.</mark>			No	
GUARDIAN CONSENT.	ELTOKTTELK VI	reenth find theent	THOWREGO	ites	
2. Are you sick today with an acute illness or few IF YES, DO NOT VACCINATE.			Yes	No	
**FOR ADMITTED PATIENTS, PROCEED VINDIVIDUAL IS CONSIDERED MEDICALLY		VACCINATION WILL	OCCUR IF/W	HEN	
3. Have you received monoclonal antibodies or COVID-19 within the past ninety (90) days? IF YES, DO NOT VACCINATE. **VACCINATION CAN OCCUR 90 DAYS FICONVALESCENT PLASMA.	•		Yes	No	
4. Have you received any non-COVID-19 vaccing YES, DO NOT VACCINATE. **VACCINATION CAN OCCUR 14 DAYS A **FOR ADMITTED PATIENTS, PROCEED V	FTER NON-COVID		Yes	No	
5. Have you had or been told that you had an im allergic reaction to any <u>COVID-19 vaccines or vaccines or vaccine</u> (See full list below for vaccine components liste Polysorbate. Note: PEG is in mRNA vaccines at colonoscopy procedures. Polysorbate 80 is in J&	vaccine components? ed by vaccine type. The nd is found in some m	nis includes polyethylen nedications such as laxar	e glycol (PEG) attives and prepar	and ations for	
Allergy to Pfizer vaccine or component (see ing Allergy to Moderna vaccine or component (see Allergy to Janssen (J&J) vaccine or component	ingredient list) (see ingredient list)		Yes Yes Yes	No No No	

IF YES TO ALLERGY TO PFIZER AND/OR ITS COMPONENTS, DO NOT ADMINISTER <u>PFIZER OR MODERNA</u>
IF YES TO ALLERGY TO MODERNA AND/OR ITS COMPONENTS, DO NOT ADMINISTER <u>PFIZER OR</u>
MODERNA

IF YES TO ALLERGY TO JANSSEN (J&J) AND/OR ITS COMPONENTS, DO NOT ADMINISTER JANSSEN (J&J))

NOTE: Individuals with an allergy to a mRNA vaccine (Pfizer or Moderna) or its ingredients are eligible to receive the Janssen (J&J) vaccine. However, these individuals should discuss the risks/benefits with their provider as described in question #6 below and stay for 30-minutes of observation, following vaccination. The same is true for individuals with an allergy to the Janssen (J&J) vaccine or ingredients. These individuals are eligible to receive the Pfizer or Moderna vaccines, but they should discuss the risks/benefits with their provider and stay for 30 minutes of observation following vaccination. Note that per CDC, individuals with an allergy to mRNA COVID-19 vaccine or its components who are considering J&J or vice versa should consider consultation with an allergist because of the cross-reactivity between ingredients in mRNA and J&J vaccines to help determine if individual can safely receive vaccination in this setting of mRNA or J&J allergy. It would be up to the individual to decide to pursue this option.

6. Do you have a history of any immediate allergic reactions of any severity* (definition below)		Yes _	_No
to any vaccines OR to injectable therapy (i.e., intramuscular, intravenous or subcutaneous)?			
IF YES, IT IS OKAY TO VACCINATE AS LONG AS INDIVIDUAL DOES NOT HAVE A CON	TRAIND	ICAT1	<mark>ON</mark>
TO VACCINATION (SEE QUESTION 5) AND HAS SPOKEN WITH HIS/HER PROVIDER OR	A RESO	URCE	
NURSE/LICENSED INDEPENDENT PRACTITIONER (LIP) AT VACCINE SITE AND UNDER			RE IS
AN ELEVATED RISK OF ALLERGIC REACTION. IF INDIVIDUAL HAS NOT SPOKEN WITH	H HIS/HF	ER	
PROVIDER, THEN INDIVIDUAL IS REQUIRED TO SPEAK WITH VACCINE SITE RESOUR	CE NURS	SE/LIP	AS
AN ALTERNATIVE FOR PURPOSES OF RISK ASSESSMENT. SEE VACCINE RECIPIENT IN	IFORMA	TION	
REGARDING DETAILS ON RISK ASSESSMENT. IF THE ALLERGY IS TO AN mRNA COVID	D-19 VA	CCINE	E AND
INDIVIDUAL IS RECEIVING J&J VACCINE OR VICE VERSA, CDC RECOMMENDS THAT	THE IND	IVIDU	JAL
CONSULT WITH AN ALLERGIST PRIOR TO VACCINATION. IT WOULD BE UP TO THE IN	<mark>vdividu</mark>	AL TO	<mark>)</mark>
DECIDE TO PURSUE THIS OPTION. (FOR MORE DETAILS SEE QUESTION #5.)			
INDIVIDUAL REQUIRES 30-MINUTE WAITING PERIOD.			
7. Do you have a history of anaphylaxis due to any other cause	_Yes	N	Vo
not already mentioned (i.e., not related to COVID-19 vaccines, or to vaccines or injectables)?			
Examples include but are not limited to: food allergies, oral medication, insect, venom, latex, etc.			
IF YES, IT IS OKAY TO VACCINATE.			
INDIVIDUAL REQUIRES 30-MINUTE WAITING PERIOD.			
		_	_
\mathcal{L}	_Yes	N	No.
IF YES, IT IS OKAY TO VACCINATE BUT USE FINE GAUGE NEEDLE (23- OR 25-GAUGE)			
AND APPLY PRESSURE TO VACCINATION SITE FOR 2 MINUTES.			
	• • • •	47.	
EUA or VIS	provided	on thi	s date
Vaccinator Printed Name and Signature and Date			

*Immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria (hives), angioedema (swelling), respiratory distress such as shortness of breath, wheezing, stridor or anaphylaxis that occur within four hours following administration

Pfizer vaccine components are:

COVID-19 mRNA Vaccine BNT 162b2 concentrate for solution for injection

ALC-0315 = (4-hydroxybutyl) azanediyl)bis (hexane-6,1-diyl)bis(2-hexyldecanoate),

ALC-0159 = 2 - [(polyethylene glycol) - 2000] - N, N-ditetradecylacetamide,

1,2-Distearoyl-sn-glycero-3-phosphocholine, cholesterol,

potassium chloride,

potassium dihydrogen phosphate,

sodium chloride,

disodium hydrogen phosphate dihydrate, sucrose,

water for injections

Moderna vaccine components are:

COVID-19 Vaccine contains 100 mcg of nucleoside- modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.

Each dose of the Moderna COVID-19 Vaccine contains the following ingredients: a total lipid content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), 0.31 mg tromethamine, 1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid, 0.12 mg sodium acetate, and 43.5 mg sucrose.

Janssen (Johnson & Johnson) vaccine components are:

Each 0.5 mL dose of Janssen COVID-19 Vaccine is formulated to contain 5×10^{10} virus particles (VP) and the following inactive ingredients: citric acid monohydrate (0.14 mg), trisodium citrate dihydrate (2.02 mg), ethanol (2.04 mg), 2-hydroxypropyl-β-cyclodextrin (HBCD) (25.50 mg), polysorbate-80 (0.16 mg), sodium chloride (2.19 mg). Each dose may also contain residual amounts of host cell proteins (\leq 0.15 mcg) and/or host cell DNA (\leq 3 ng).